Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT02227251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Study identification
- NCT ID
- NCT02227251
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 244 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2014 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Oct 1, 2026
2014 – 2026
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UACC Arizona | Tucson | Arizona | 85704 | — |
| University of California San Francisco | San Francisco | California | — | — |
| University of California Los Angeles (UCLA) | Santa Monica | California | 90404 | — |
| Boca Raton Cancer Research Medical Center | Plantation | Florida | — | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Robert H. Lurie Comprehensive Cancer Center/Northwestern University | Chicago | Illinois | — | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Tufts Medical Center | Boston | Massachusetts | — | — |
| Lahey Clinic | Burlington | Massachusetts | — | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | — | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | — | — |
| Clinical Research Alliance | Lake Success | New York | — | — |
| New York Presbyterian Hospital/ Cornell Medical College | New York | New York | 10065 | — |
| Stony Brook University Hospital | Stony Brook | New York | 11794 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | — | — |
| University of Oklahoma | Oklahoma City | Oklahoma | — | — |
| Greenville Hospital System | Greenville | South Carolina | 29605 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Virginia Mason Hospital & Medical Center | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02227251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02227251 live on ClinicalTrials.gov.